Alpha Mannosidosis Market 2022 - By Therapy Type (Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT)), By Indication (Type I, Type II, Type III), By End User (Hospital, Specialty Clinics), And By Region, Opportunities And Strategies – Global Forecast To 2030

Starting Price : $5000.00 | Pages : 192 | Published : December 2021 | SKU CODE : | | Format :

Request Sample

Alpha Mannosidosis Market Definition

The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis by entities (organizations, sole traders and partnerships) that provide treatment for alpha mannosidosis. Alpha-mannosidosis (a-mannosidosis) is a rare lysosomal storage disorder with an autosomal recessive inheritance caused by mutations in the gene encoding for the lysosomal a-d-mannosidase. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Key therapies in the treatment of Alpha Mannosidosis include enzyme replacement therapy and bone marrow transplants.

Alpha-mannosidosis is a rare genetic inherited condition caused by mutations of the MAN2B1 gene that affects the organs and tissues of the person suffering from the disease.  It is characterized by intellectual disability, hearing loss, ataxia, skeletal abnormalities, and coarse facial features.  The treatment therapy for this condition focuses on detecting and preventing polysaccharide accumulations within mutant cells, which can cause harm to tissue, organs, and eventually death. Polysaccharides are defined as larger molecules composed of several linked sugar molecules.

Alpha Mannosidosis Market Size

The global alpha mannosidosis market reached a value of nearly $7.60 million in 2020 to $70.06 million in 2025 at a rate of 55.9%. The alpha mannosidosis market is then expected to grow at a CAGR of 15.4% from 2025 and reach $143.14 million in 2030.  

Growth of the alpha mannosidosis market will benefit from regulatory support, market exclusivity of orphan drugs, reimbursement for the therapies, orphan drug manufacturers’ incentives, growth in research and development, increase in investments in genetic therapies, rise in healthcare expenditure, and market exclusivity of orphan drugs. The alpha mannosidosis market was restrained by high costs of therapy and orphan drugs, low healthcare expenditure and coronavirus pandemic.

Alpha Mannosidosis Market Drivers

The key drivers of the alpha mannosidosis market include:

Regulatory Support

Rising regulatory support for the drug approval of rare diseases in alpha mannosidosis is expected to drive the alpha mannosidosis market in forecast period. The inherently small population of patients with a rare disease can also make conducting clinical trials difficult. But to tackle this, in 2021, FDA announced providing support for the development and evaluation of new treatments for rare diseases making it a key priority. The FDA has authority to grant orphan-drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including: tax credits for qualified clinical trials, exemption from user fees and potential seven years of market exclusivity after approval.  Thus, rising support for regulatory bodies will propel the alpha mannosidosis market.

Alpha Mannosidosis Market Restraints

The key restraints on the alpha mannosidosis market include:

High Costs Of Therapy And Orphan Drugs

High costs associated with bone marrow transplant (BMT), enzyme replacement therapy (ERT), peripheral blood stem cell transplantation (PBSCT), and gene therapy for the treatment of alpha mannosidosis is a major issue faced by citizens of many countries. The cost of orphan drugs is higher when compared to other generic, and branded therapies or drugs caused by market exclusivity. Political uncertainty and constant economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for alpha mannosidosis has influenced the health conditions of the population and has led to a low average life expectancy. For example, the cost for bone marrow transplantation starts at €97,000 ($114,441) and depends on the level of the hospital.

Alpha Mannosidosis Market Trends

Major trends influencing the alpha mannosidosis market include:

Enzyme Replacement Therapy

The use of enzyme replacement therapy is increasingly gaining traction in the alpha mannosidosis market. Lamzede (velmanase alfa) is a long-term enzyme replacement therapy in adults, adolescents, and children to help treat mild to moderate forms of alpha-mannosidosis. It is a recombinant human alpha-mannosidase developed as an intravenous enzyme replacement therapy (ERT) to administer the medicine into the bloodstream in order to replace the function of the deficient enzyme in the body. The therapy aims to normalize oligosaccharide levels in the body, which ultimately prevents the progression of the disease and the formation of abnormalities. For instance, as per a study conducted in 2018, the benefits of Lamzede were assessed in 25 patients in a multi-centre, randomized, double-blind, placebo-controlled parallel group trial over 52 weeks showed an improvement in exercise capacity, a decrease of serum oligosaccharide to normal levels, and pulmonary function in certain patients.      

Hematopoietic Stem Cell Transplantation (HSCT)

Pharmaceutical companies are increasingly adopting the use of Hematopoietic Stem Cell Transplantation (HSCT) to treat alpha mannosidosis. HSCT or HCT has been shown to improve neurocognitive and sensorineural function in patients along with improvements in skeletal malformations. In some patients, there is an improvement in hearing loss as well as intellectual stabilization. An improvement in adaptive skills and verbal memory function can be found in certain patients.  For instance, in 2012, Mynarek et al reported the results of the analysis of 17 patients who had undergone HCT. Due to HCT’s nature, 2 of the 17 patients had passed away with the rest showing improvements in different factors such as an improvement in hearing ability.

Opportunities And Recommendations In The Alpha Mannosidosis Market

Opportunities –The top opportunities in the alpha mannosidosis market segmented by therapy type will arise in the others segment, which will gain $26.8 million of global annual sales by 2025. The top opportunities in the alpha mannosidosis market segmented by indication will arise in type III segment, which will gain $28.9 million of global annual sales by 2025. The top opportunities in the alpha mannosidosis market segmented by end-user will arise in hospitals segment, which will gain $49.0 million of global annual sales by 2025. The alpha mannosidosis market size will gain the most in the USA at $30.7 million.

Recommendations-To take advantage of the opportunities, The Business Research Company recommends the alpha mannosidosis companies to offer enzyme replacement therapy, focus on hematopoietic stem cell transplantation (HSCT), focus on cisterna magna infusion, expand through partnerships and collaborations, expand in emerging markets, expand in geographies with reimbursement support, expand for educational and research purposes, offer value-based pricing, focus on securing long-term contracts with healthcare institutions, conduct informative seminars and fairs, partnering with key healthcare providers, participate in trade shows and awareness events, increase visibility through business websites and listing websites and focus on hospitals and other diagnostic centers.

Alpha Mannosidosis Market Segmentation

The alpha mannosidosis market is segmented by therapy type, by indication and by end-user.
By Therapy Type -
The alpha mannosidosis market is segmented by therapy type into:
    • a) Bone Marrow Transplant (BMT)
    • b) Enzyme Replacement Therapy (ERT)
    • c) Peripheral Blood Stem Cell Transplantation (PBSCT)
The enzyme replacement therapy (ERT) segment of the alpha mannosidosis market accounted for $7.6 million in 2020 and expected to reach a value of $23.5 million by 2025, at a CAGR of 25.3%.
By Indication -
The alpha mannosidosis market is segmented by indication into:
    • a) Type I
    • b) Type II
    • c) Type III
The type II was the largest segment of the alpha mannosidosis market segmented by indication type, accounting for 45% of the total in 2020. Going forward, the type III segment is expected to be the fastest growing segment in the alpha mannosidosis market segmented by indication type, at a CAGR of 18.1% during 2020-2025.
By End User -
The alpha mannosidosis market is segmented by end user into:
    • d) Hospital
    • e) Specialty Clinics
The hospitals market was the largest segment of the alpha mannosidosis market segmented by end-user, accounting for 81.5% of the total in 2020. Going forward, the specialty clinics segment is expected to be the fastest growing segment in the alpha mannosidosis market segmented by end-user, at a CAGR of 16.6% during 2020-2025.
By Geography – The alpha mannosidosis market is segmented by geography into
      o Asia Pacific
      • • China
      • • India
      • • Japan
      • • Australia
      • • Indonesia
      • • South Korea
      o North America
      • • USA
      o South America
      • • Brazil
      o Western Europe
      • • France
      • • Germany
      • • UK
      o Eastern Europe
      • • Russia
      o Middle East
      o Africa
North America was the largest region in the alpha mannosidosis market in 2020. It will be followed by the Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the alpha mannosidosis market will be Asia Pacific and Western Europe where growth will be at CAGRs of 38.1% and 14.0% respectively during 2025-2030.

Alpha Mannosidosis Competitive Landscape

Major Competitors are:

  • Chiesi Farmaceutici S.p.A.
  • Other Competitors Include:

  • Mitsubishi Tanabe Pharma
  • Oxford Biomedica plc
  • Santen Pharmaceutical Co.
  • Therapeutic Innovation Australia
  • GenScript
  • Cellular Biomedicine Group
  • GE Healthcare
  • inStem
  • Nikon CeLL innovation Co. Ltd.
  • Novartis AG
  • Amgen
  • Pfizer
  • Centogene
  • Zymenex A/S
  • Albumedix Ltd
  • Kite Pharma
  • Gilead Sciences
  • Catalent
  • Oxford BioTherapeutics
  • Freeline Therapeutics
  • Avectas
  • Lonza
  • DiNAQOR AG
  • Vivet Therapeutics
  • Allergan
  • PsiOxus Therapeutics
  • Merck
  • Herantis Pharma Plc
  • Biocad
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Johnson & Johnson
  • Eli Lilly and Company
  • AstraZeneca
  • Bayer AG
  • Ultragenyx
  • PTC Therapeutics
  • GlaxoSmithKline plc
  • The Takeda Pharmaceutical Company Limited
  • Middle East Gene Therapy Company
  • DEVA
  • Biotchpharma
  • Gene Vector Technologies
  • BrainStorm Cell Therapeutics
  • Pluristem
  • Biogen SA
  • Sanofi
  • Adcock Ingram
    1. Table Of Contents

      1. Alpha Mannosidosis Market Executive Summary

      2. Table of Contents

      3. List of Figures

      4. List of Tables

      5. Report Structure

      6. Introduction

      6.1. Segmentation By Geography

      6.2. Segmentation By Therapy Type

      6.3. Segmentation By Indication

      6.4. Segmentation By End-User

      7. Alpha Mannosidosis Market Characteristics

      7.1. Market Definition

      7.2. Segmentation By Therapy Type

      7.2.1. Bone Marrow Transplant (BMT)

      7.2.2. Enzyme Replacement Therapy (ERT)

      7.2.3. Others

      7.3. Segmentation By Indication

      7.3.1. Type I

      7.3.2. Type II

      7.3.3. Type III

      7.4. Market Segmentation By End-User

      7.4.1. Hospitals

      7.4.2. Specialty Clinics

      8. Alpha Mannosidosis Market Trends And Strategies

      8.1. Enzyme Replacement Therapy

      8.2. Hematopoietic Stem Cell Transplantation (HSCT)

      8.3. Cisterna Magna Infusion

      8.4. Global Research Initiatives And Funding

      9. Impact Of COVID-19 On The Alpha Mannosidosis Market

      9.1. Introduction

      9.2. Impact On Research And Development Activities And Clinical Trials

      9.3. COVID-19 Impact On Treatment

      9.4. Impact On Patients And Healthcare Providers

      9.5. Future Outlook

      10. Global Alpha Mannosidosis Market Size And Growth

      10.1. Market Size

      10.2. Forecast Market Growth, 2020 –2030F, Value ($ Million)

      10.2.1. Drivers Of The Market 2020 – 2025

      10.2.2. Restraints On The Market 2020 – 2025

      11. Global Alpha Mannosidosis Market Segmentation

      11.1. Global Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      11.2. Global Alpha Mannosidosis Market, Segmentation By Indication, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      11.3. Global Alpha Mannosidosis Market, Segmentation By End-User, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      12. Alpha Mannosidosis Market, Regional And Country Analysis

      12.1. Global Alpha Mannosidosis Market, By Region, Historic and Forecast, 2020, 2025F-2030F, Value ($ Million)

      12.2. Global Alpha Mannosidosis Market, By Country, Historic and Forecast, 2020, 2025F-2030F, Value ($ Million)

      13. Asia-Pacific Alpha Mannosidosis Market

      13.1. Asia Pacific Alpha Mannosidosis Market Overview

      13.1.1. Region Information

      13.1.2. Market Information

      13.1.3. Impact Of COVID-19

      13.1.4. Background Information

      13.1.5. Government Initiatives

      13.1.6. Regulations

      13.1.7. Regulatory Bodies

      13.1.8. Major Associations

      13.1.9. Taxes Levied

      13.1.10. Corporate Tax Structure

      13.1.11. Investments

      13.1.12. Major Companies

      13.2. Asia-Pacific Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      13.3. Asia-Pacific Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      13.4. Asia-Pacific Alpha Mannosidosis Market: Country Analysis

      13.5. China Alpha Mannosidosis Market

      13.6. China Alpha Mannosidosis Market Overview

      13.6.1. Country Information

      13.6.2. Market Information

      13.6.3. Impact Of COVID-19

      13.6.4. Background Information

      13.6.5. Government Initiatives

      13.6.6. Regulations

      13.6.7. Regulatory Bodies

      13.6.8. Major Associations

      13.6.9. Taxes Levied

      13.6.10. Corporate Tax Structure

      13.6.11. Investments

      13.6.12. Major Companies

      13.7. China Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      13.8. China Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      13.9. India Alpha Mannosidosis Market

      13.10. India Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      13.11. India Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      13.12. Japan Alpha Mannosidosis Market

      13.13. Japan Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      13.14. Japan Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      13.15. Australia Alpha Mannosidosis Market

      13.16. Australia Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      13.17. Australia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      13.18. Indonesia Alpha Mannosidosis Market

      13.19. South Korea Alpha Mannosidosis Market

      13.20. South Korea Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      13.21. South Korea Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      14. Western Europe Alpha Mannosidosis Market

      14.1. Western Europe Alpha Mannosidosis Market Overview

      14.1.1. Region Information

      14.1.2. Market Information

      14.1.3. Impact Of COVID-19

      14.1.4. Background Information

      14.1.5. Government Initiatives

      14.1.6. Regulations

      14.1.7. Regulatory Bodies

      14.1.8. Major Associations

      14.1.9. Taxes Levied

      14.1.10. Corporate Tax Structure

      14.1.11. Investments

      14.1.12. Major Companies

      14.2. Western Europe Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      14.3. Western Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      14.4. Western Europe Alpha Mannosidosis Market: Country Analysis

      14.5. UK Alpha Mannosidosis Market

      14.6. UK Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      14.7. UK Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      14.8. Germany Alpha Mannosidosis Market

      14.9. Germany Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      14.10. Germany Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      14.11. France Alpha Mannosidosis Market

      14.12. France Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      14.13. France Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      15. Eastern Europe Alpha Mannosidosis Market

      15.1. Eastern Europe Alpha Mannosidosis Market Overview

      15.1.1. Region Information

      15.1.2. Market Information

      15.1.3. Impact Of COVID-19

      15.1.4. Background Information

      15.1.5. Government Initiatives

      15.1.6. Regulations

      15.1.7. Regulatory Bodies

      15.1.8. Major Associations

      15.1.9. Taxes Levied

      15.1.10. Corporate Tax Structure

      15.1.11. Investments

      15.1.12. Major Companies

      15.2. Eastern Europe Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      15.3. Eastern Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      15.4. Eastern Europe Alpha Mannosidosis Market: Country Analysis

      15.5. Russia Alpha Mannosidosis Market

      15.6. Russia Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      15.7. Russia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      16. North America Alpha Mannosidosis Market

      16.1. North America Alpha Mannosidosis Market Overview

      16.1.1. Region Information

      16.1.2. Market Information

      16.1.3. Impact of COVID-19

      16.1.4. Background Information

      16.1.5. Government Initiatives

      16.1.6. Regulations

      16.1.7. Regulatory Bodies

      16.1.8. Associations

      16.1.9. Taxes Levied

      16.1.10. Corporate Tax Structure

      16.1.11. Investments

      16.1.12. Major Companies

      16.2. North America Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      16.3. North America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      16.4. North America Alpha Mannosidosis Market: Country Analysis

      16.5. USA Alpha Mannosidosis Market

      16.6. USA Alpha Mannosidosis Market Overview

      16.6.1. Country Information

      16.6.2. Market Information

      16.6.3. Impact of COVID-19

      16.6.4. Background Information

      16.6.5. Government Initiatives

      16.6.6. Regulations

      16.6.7. Regulatory Bodies

      16.6.8. Associations

      16.6.9. Taxes Levied

      16.6.10. Corporate Tax Structure

      16.6.11. Investments

      16.6.12. Major Companies

      16.7. USA Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      16.8. USA Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      17. South America Alpha Mannosidosis Market

      17.1. South America Alpha Mannosidosis Market Overview

      17.1.1. Region Information

      17.1.2. Market Information

      17.1.3. Impact of COVID-19

      17.1.4. Background Information

      17.1.5. Government Initiatives

      17.1.6. Regulations

      17.1.7. Regulatory Bodies

      17.1.8. Major Associations

      17.1.9. Taxes Levied

      17.1.10. Corporate Tax Structure

      17.1.11. Investments

      17.1.12. Major Companies

      17.2. South America Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      17.3. South America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      17.4. South America Alpha Mannosidosis Market: Country Analysis

      17.5. Brazil Alpha Mannosidosis Market

      17.6. Brazil Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      17.7. Brazil Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      18. Middle East Alpha Mannosidosis Market

      18.1. Middle East Alpha Mannosidosis Market Overview

      18.1.1. Region Information

      18.1.2. Market Information

      18.1.3. Impact Of COVID-19

      18.1.4. Background Information

      18.1.5. Government Initiatives

      18.1.6. Regulations

      18.1.7. Regulatory Bodies

      18.1.8. Major Associations

      18.1.9. Taxes Levied

      18.1.10. Corporate Tax Structure

      18.1.11. Investments

      18.1.12. Major Companies

      18.2. Middle East Alpha Mannosidosis Market, Forecast Market Growth, 2020 –2030F, Value ($ Million)

      18.3. Middle East Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, Value ($ Million)

      19. Africa Alpha Mannosidosis Market

      19.1. Africa Alpha Mannosidosis Market Overview

      19.1.1. Region Information

      19.1.2. Market Information

      19.1.3. Impact of COVID-19

      19.1.4. Background Information

      19.1.5. Government Initiatives

      19.1.6. Regulations

      19.1.7. Regulatory Bodies

      19.1.8. Major Associations

      19.1.9. Taxes Levied

      19.1.10. Corporate Tax Structure

      19.1.11. Investments

      19.1.12. Major Companies

      20. Global Alpha Mannosidosis Market Competitive Landscape

      20.1. Company Profiles

      20.2. Chiesi Farmaceutici S.p.A.

      20.2.1. Company Overview

      20.2.2. Products And Services.

      20.2.3. Business Strategy

      20.2.4. Financial Overview

      21. Key Mergers And Acquisitions In The Alpha Mannosidosis Market

      21.1. Sanofi Acquired Kadmon

      21.2. Jasper Therapeutics Reverse Merger with Amplitude Healthcare Acquisition Corp

      21.3. Albumedix Ltd. Collaboration With Cell and Gene Therapy Catapult

      21.4. Elli Lilly And Company Acquired Prevail Therapeutics

      21.5. Chiesi Farmaceutici Acquired Rights to Ferriprox®

      21.6. Vertex Pharmaceuticals Incorporation Acquired Semma Therapeutics

      21.7. Merck Merged With (MoU) GenScript

      21.8. Pfizer Acquired Vivet Therapeutics

      22. Alpha Mannosidosis Market Pipeline Analysis

      23. Alpha Mannosidosis Market Opportunities And Strategies

      23.1. Global Alpha Mannosidosis Market In 2025 – Countries Offering Most New Opportunities

      23.2. Global Alpha Mannosidosis Market In 2025 – Segments Offering Most New Opportunities

      23.3. Global Alpha Mannosidosis Market In 2025 – Growth Strategies

      23.3.1. Market Trend Based Strategies

      23.3.2. Competitor Strategies

      24. Alpha Mannosidosis Market, Conclusions And Recommendations

      24.1. Conclusions

      24.2. Recommendations

      24.2.1. Product

      24.2.2. Place

      24.2.3. Price

      24.2.4. Promotion

      24.2.5. People

      25. Appendix

      25.1. Market Data Sources

      25.2. Research Methodology

      25.3. Currencies

      25.4. Research Inquiries

      25.5. The Business Research Company

      25.6. Copyright and Disclaimer

    List Of Tables

      Table 1: Global Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 2: Global Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 3: Global Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 4: Global Alpha Mannosidosis Market, Segmentation By Indication, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 5: Global Alpha Mannosidosis Market, Segmentation By Indication, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 6: Global Alpha Mannosidosis Market, Segmentation By End-User, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 7: Global Alpha Mannosidosis Market, Segmentation By End-User, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 8: Global Alpha Mannosidosis Market, By Region, Historic and Forecast, 2020, 2025F-2030F, %
    • Table 9: Global Alpha Mannosidosis Market, By Region, Historic and Forecast, 2020, 2025F-2030F, $ Million
    • Table 10: Global Alpha Mannosidosis Market, By Country, Historic and Forecast, 2020, 2025F-2030F, %
    • Table 11: Global Alpha Mannosidosis Market, By Country, Historic and Forecast, 2020, 2025F-2030F, $ Million
    • Table 12: Asia-Pacific Vaccine Market, COVID-19 Vaccines Approvals
    • Table 13: Asia-Pacific Vaccine Market, Number of COVID-19 Doses Administered, By Country
    • Table 14: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 15:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 16: Asia-Pacific, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 17: Asia Pacific GDP Per Capita, 2015-2020, $
    • Table 18: Asia-Pacific, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 19: Asia-Pacific Alpha Mannosidosis Market, Biologics Market Size, By Country, 2015-2025, $ Billion
    • Table 20: Asia-Pacific Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 21: Asia-Pacific Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 22: Asia-Pacific Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 23: China Vaccine Market, COVID-19 Vaccines Approvals
    • Table 24:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 25: China, Population By Age Group, 2015-2025, Thousands
    • Table 26: China GDP Per Capita, 2015-2020, $
    • Table 27: China, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 28: China Alpha Mannosidosis Market, Biologics Market Size, 2015-2025, $ Billion
    • Table 29: China Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 30: China Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 31: China Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 32: India Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 33: India Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 34: India Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 35: Japan Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 36: Japan Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 37: Japan Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 38: Australia Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 39: Australia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 40: Australia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 41: South Korea Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 42: South Korea Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 43: South Korea Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 44: Western Europe Vaccine Market, COVID-19 Vaccines Approvals
    • Table 45: Western Europe Vaccine Market, Number of COVID-19 Doses Administered, By Country
    • Table 46:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 47:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 48: Western Europe, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 49: Western Europe GDP Per Capita, 2015-2020, $
    • Table 50: Western Europe, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 51: Western Europe Alpha Mannosidosis Market, Biologics Market Size, By Country, 2015-2025, $ Billion
    • Table 52: Western Europe Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 53: Western Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 54: Western Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 55: UK Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 56: UK Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 57: UK Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 58: Germany Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 59: Germany Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 60: Germany Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 61: France Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 62: France Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 63: France Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 64: Western Europe Vaccine Market, COVID-19 Vaccines Approvals
    • Table 65: Eastern Europe Vaccine Market, Number of COVID-19 Doses Administered, By Country
    • Table 66:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 67:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 68: Eastern Europe, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 69: Eastern Europe GDP Per Capita, 2015-2020, $
    • Table 70: Eastern Europe, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 71: Eastern Europe Alpha Mannosidosis Market, Biologics Market Size, By Country, 2015-2025, $ Billion
    • Table 72: Eastern Europe Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 73: Eastern Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 74: Eastern Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 75: Russia Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 76: Russia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 77: Russia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 78: North America Vaccine Market, COVID-19 Vaccines Approvals
    • Table 79: North America Vaccine Market, Number of COVID-19 Doses Administered, By Country
    • Table 80:  North America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 81:  North America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 82: North America, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 83: North America GDP Per Capita, 2015-2020, $
    • Table 84: North America, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 85: North America Alpha Mannosidosis Market, Biologics Market Size, By Country, 2015-2025, $ Billion
    • Table 86: North America Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 87: North America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 88: North America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 89: USA Vaccine Market, COVID-19 Vaccines Approvals
    • Table 90:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 91: USA, Population By Age Group, 2015-2025, Thousands
    • Table 92: USA GDP Per Capita, 2015-2020, $
    • Table 93: USA Home, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 94: USA Alpha Mannosidosis Market, Biologics Market Size, 2015-2025, $ Billion
    • Table 95: USA Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 96: USA Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 97: USA Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 98: South America Vaccine Market, COVID-19 Vaccines Approvals
    • Table 99: South America Vaccine Market, Number of COVID-19 Doses Administered, By Country
    • Table 100:  South America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 101:  South America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 102: South America, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 103: South America GDP Per Capita, 2015-2020, $
    • Table 104: South America, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 105: South America Alpha Mannosidosis Market, Biologics Market Size, By Country, 2015-2025, $ Billion
    • Table 106: South America Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 107: South America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 108: South America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 109: Brazil Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 110: Brazil Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 111: Brazil Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 112: Middle East Vaccine Market, COVID-19 Vaccines Approvals
    • Table 113: Middle East Vaccine Market, Number of COVID-19 Doses Administered, By Country
    • Table 114:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 115:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 116: Middle East, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 117: Middle East GDP Per Capita, 2015-2020, $
    • Table 118: Middle East Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 119: Middle East Alpha Mannosidosis Market, Biologics Market Size, By Country, 2015-2025, $ Billion
    • Table 120: Middle East Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Table 121: Middle East Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Table 122: Middle East Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, $ Million
    • Table 123: Africa Vaccine Market, COVID-19 Vaccines Approvals
    • Table 124: Middle East Vaccine Market, Number of COVID-19 Doses Administered, By Country
    • Table 125:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 126:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 127: Africa, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 128: Africa GDP Per Capita, 2015-2020, $
    • Table 129: Africa Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 130: Africa Alpha Mannosidosis Market, Biologics Market Size, By Country, 2015-2025, $ Billion
    • Table 131: Global Alpha Mannosidosis Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Table 132: Chiesi Farmaceutici S.p.A. – Financial Overview, 2016 - 2020, $ Billion
    • Table 133: Global Alpha Mannosidosis Market, Pipeline Analysis
    • Table 134: Global Alpha Mannosidosis Market Size Gain ($ Million), 2020 – 2025, By Country
    • Table 135: Global Alpha Mannosidosis Market Size Gain ($ Million), Segmentation By Therapy Type, 2020 – 2025
    • Table 136: Global Alpha Mannosidosis Market Size Gain ($ Million), Segmentation By Indication, 2020 – 2025
    • Table 137: Global Alpha Mannosidosis Market Size Gain ($ Million), Segmentation By End-User, 2020 – 2025
    • Table 138: Alpha Mannosidosis- Market Data Sources

    List Of Figures

      Figure 1: Global Alpha Mannosidosis Market Segmentation By Therapy Type
    • Figure 2: Global Alpha Mannosidosis Market Segmentation By Indication
    • Figure 3: Global Alpha Mannosidosis Market Segmentation By End-User
    • Figure 4: Global Alpha Mannosidosis Market, Forecast, 2020 –2030F, $ Million
    • Figure 5: Global Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 6: Global Alpha Mannosidosis Market, Segmentation By Indication, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 7: Global Alpha Mannosidosis Market, Segmentation By End-User, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 8: Global Alpha Mannosidosis Market, By Region, Historic and Forecast, 2020, 2025F-2030F, %
    • Figure 9: Global Alpha Mannosidosis Market, By Country, Historic and Forecast, 2020, 2025F-2030F, %
    • Figure 10: Asia-Pacific Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 11: Asia-Pacific Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 12: China Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 13: China Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 14: India Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 15: India Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 16: Japan Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 17: Japan Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 18: Australia Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 19: Australia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 20: South Korea Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 21: South Korea Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 22: Western Europe Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 23: Western Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 24: UK Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 25: UK Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 26: Germany Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 27: Germany Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 28: France Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 29: France Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 30: Eastern Europe Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 31: Eastern Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 32: Russia Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 33: Russia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 34: North America Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 35: North America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 36: USA Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 37: USA Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 38: South America Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 39: South America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 40: Brazil Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 41: Brazil Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 42: Middle East Alpha Mannosidosis Market, Forecast, 2020 – 2030F, $ Million
    • Figure 43: Middle East Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic And Forecast, 2020, 2025F-2030F, %
    • Figure 44: Global Alpha Mannosidosis Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Figure 45: Chiesi Farmaceutici S.p.A.– Financial Overview, 2016 – 2020, $ Billion
    Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Vaccines Market 2021 - By Type (Anti-Infective Vaccines, Anti-Cancer Vaccines, Others), By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Other Technologies), By Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, Other Route of Administration), By Valance (Monovalent, Multivalent), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Institutional Sales), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Ophthalmology Drugs Market - By Type (Antiglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Prescription Type (OTC Drugs, Prescription Drugs), By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Drug Variation (Branded Drugs, Generic Drugs), And, By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Musculoskeletal Drugs Market Global Briefing 2018
    View Report
    Respiratory Drugs Market Global Briefing 2018
    View Report
    Antisense And RNAi Therapeutics Market 2021- By Technology (RNA Interference, Antisense RNA), By Route Of Administration (Intravenous injections, Intra Dermal injunctions, Other delivery methods), By Indication (Oncology, Cardiovascular device, Respiratory disorders, Neurological disorders, Infectious disease), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report

    Call Us

    +1 3156230293

    (Americas)

    +44 2071930708

    (Europe)

    +91 8897263534

    (Asia & Others)